For example, an anti-claudin-18.2 mAb is undergoing clinical study for the use in the treatment of gastric (phase III study) and pancreatic cancer (phase II study) [NCT03504397; NCT03816163]. This evidence concerns the gene CLDN18 and familial pancreatic carcinoma.